EQUITY RESEARCH - RESULTS FLASH



MEGA TB

THAILAND / COMMERCE



TARGET PRICE

UP/DOWNSIDE

TP vs CONSENSUS

CLOSE



THB56.00

THB37.50

+49.3%

+16.7%

3Q24 results at first glance

Despite in-line core profit, details look weak

Highlights


- The significant appreciation of the Thai baht led to higher-thanexpected FX losses for MEGA in 3Q24, amounting to THB601m. This resulted in a 3Q24 net profit of only THB383m (-25.4% q-q, -28.6% y-y).
- Excluding the FX loss, the core profit would be THB544m (-2.3% q-q, +3.5% y-y), in line with our expectation. Despite this, the overall picture is not very positive due to the continued decline in consumer product sales in Myanmar and the impact of the strong baht on revenue.
- The reported sales revenue in 3Q24 increased by 1.2% q-q and 5.2% y-y to THB4b, but this figure has not yet been adjusted for the impact of the dual currency rate effect in Myanmar. After normalizing this FX impact, the revenue from its distribution business (40% of total revenue) would decline by 6.9% q-q and 20.5% y-y, dropping to THB1.4b. This marked the lowest level in at least seven quarters and pulled total sales revenue down by 4.8% q-q and 5.5% y-y to THB3.5b
- The gross margin of the distribution business has been continuously decreasing for several quarters due to the challenging situation in Myanmar. Although the impact on pharmaceutical products has been limited, the company's imported consumer goods have been continuously affected. As a result, the proportion of revenue from consumer goods has now decreased to 15% of the distribution unit's revenue, down from 30% in previous years.
- The branded business, which is more resilient to economic conditions, was also impacted by the strong Thai baht (about 75% of sales were from outside Thailand). As a result, its revenue decreased by 5.0% q-q to THB2b, primarily due to a decline in revenue from Africa.

Outlook

For 9M24, the revenue adjusted for the impact of the exchange rate in Myanmar declined by 3.5% y-y, and the rise in SG&A expenses led to a 6.9% y-y fall in core profit, which amounted to THB1.6b, or only 65% of our full-year forecast. The outlook in 4Q24 may not differ significantly from 3Q24, and thus our estimates have a downside risk. The good point, in our view, is that MEGA trades at a relatively low P/E ratio.

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	15,681	16,139	16,927	17,736
Net profit	1,993	2,444	2,598	2,715
EPS (THB)	2.29	2.80	2.98	3.11
vs Consensus (%)	-	(1.0)	(2.6)	(3.5)
EBITDA	3,285	3,201	3,389	3,535
Recurring net profit	2,699	2,444	2,598	2,715
Core EPS (THB)	3.10	2.80	2.98	3.11
EPS growth (%)	13.4	(9.4)	6.3	4.5
Core P/E (x)	12.1	13.4	12.6	12.0
Dividend yield (%)	4.3	4.1	4.4	4.6
EV/EBITDA (x)	9.2	9.4	8.8	8.4
Price/book (x)	3.5	3.3	3.2	3.0
Net debt/Equity (%)	(26.4)	(26.3)	(27.5)	(27.7)
ROE (%)	29.9	25.5	25.7	25.8



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(3.8)	(3.2)	(9.6)
Relative to country (%)	(2.2)	(13.1)	(13.1)
Mkt cap (USD m)			939
3m avg. daily turnover (USD m)			0.9
Free float (%)			40
Major shareholder	Un	istretch Co	Ltd (50%)
12m high/low (THB)		4	4.25/35.00
Issued shares (m)			871.87

Sources: Bloomberg consensus; FSSIA estimates



Jitra Amornthum


Fundamental Investment Analyst on Securities; License no. 014530 jitra.a@fssia.com, +66 2646 9966

Exhibit 1: MEGA - 3Q24 results summary

Year to Dec 31	3Q23	4Q23	1Q24	2Q24	3Q24	Cha	ange	9M23	9M24	Change	% o
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)	2024E				
Sales	3,803	4,158	3,733	3,954	4,001	1.2	5.2	11,523	11,687	1.4	72.
Cost of sales	(2,064)	(2,252)	(1,984)	(2,038)	(1,866)	(8.4)	(9.6)	(6,333)	(5,888)	(7.0)	66.
Gross profit	1,739	1,905	1,749	1,916	2,135	11.4	22.8	5,190	5,799	11.7	79.
Operating costs	(1,021)	(1,104)	(1,066)	(1,140)	(1,099)	(3.5)	7.7	(3,087)	(3,306)	7.1	73.
Operating profit	718	801	682	776	1,035	33.4	44.1	2,103	2,494	18.6	21.
Operating EBITDA	815	908	775	872	1,138	30.5	39.6	2,378	2,785	17.1	87.
Other income	27	31	22	26	32	20.8	18.0	64	80	25.7	124.
Interest expense	(8)	(5)	(5)	(9)	(10)	11.6	23.8	(27)	(25)	(6.8)	91.
Profit before tax	737	828	699	793	1,057	33.2	43.4	2,140	2,549	19.1	88.
Tax	(98)	(58)	(71)	(93)	(73)	(21.9)	(25.5)	(211)	(237)	12.4	54.
Reported net profit	536	473	478	513	383	(25.4)	(28.6)	1,519	1,373	(9.6)	56
Extraordinaries											
- Net loss from new businesses	11	10	9	0	53			30	62		
- FX loss/(gain)	(38)	138	7	(187)	(601)			194	(781)		
- Normalizing tax expense	17	0	0	0	0			(31)	0		
Core profit	526	621	494	557	544	(2.3)	3.5	1,713	1,595	(6.9)	65
Reported EPS (THB)	0.61	0.54	0.55	0.59	0.44	(25.4)	(28.6)	1.74	1.57	(9.7)	56
Core EPS (THB)	0.60	0.71	0.57	0.64	0.62	(2.3)	3.5	1.96	1.83	(6.9)	65
Key Ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)	
Gross margin	45.7	45.8	46.8	48.5	53.4	4.9	7.6	45.0	49.6	4.6	
Operating margin	19.6	20.0	18.9	20.3	26.7	6.4	7.1	18.3	21.3	3.1	
EBITDA margin	21.4	21.8	20.8	22.1	28.5	6.4	7.0	20.6	23.8	3.2	
Recurring net margin	13.8	14.9	13.2	14.1	13.6	(0.5)	(0.2)	14.9	13.6	(1.2)	
SG&A / Sales	26.8	26.6	28.6	28.8	27.5	(1.3)	0.6	26.8	28.3	1.5	
Revenue breakdown	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)					
Branded business	1,907	2,126	1,930	2,140	2,033	(5.0)	6.6	5,879	6,103	3.8	
Distribution business	1,825	1,980	1,737	1,746	1,865	6.8	2.2	5,417	5,348	(1.3)	
Normalized revenue after the dual rate effect in Myanmar	1,770	1,710	1,483	1,512	1,407	(6.9)	(20.5)	5,024	4,402	(12.4)	
OEM business	71	53	65	68	104	51.7	46.5	227	237	4.4	
Gross margin by business unit	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)	
Branded business	65.3	64.3	64.3	66.0	65.2	(0.8)	(0.1)	65.2	65.2	(0.0)	
Distribution business	25.9	26.6	27.9	27.8	23.7	(4.1)	(2.2)	23.7	26.4	2.7	
OEM business	27.9	25.6	34.9	26.1	41.3	15.2	13.4	31.2	35.2	4.0	


Sources: MEGA, FSSIA estimates

Exhibit 2: Gross margin by business



Sources: MEGA, FSSIA's compilation

Exhibit 3: Core profit and core profit margin



Sources: MEGA, FSSIA's compilation

Financial Statements

Mega Lifesciences

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	15,686	15,681	16,139	16,927	17,736
Cost of goods sold	(8,647)	(8,586)	(8,816)	(9,206)	(9,640)
Gross profit	7,040	7,095	7,323	7,720	8,097
Other operating income	80	95	65	68	71
Operating costs	(4,359)	(4,191)	(4,483)	(4,706)	(4,948)
Operating EBITDA	3,033	3,285	3,201	3,389	3,535
Depreciation	(272)	(286)	(297)	(307)	(316)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	2,761	2,999	2,904	3,082	3,219
Net financing costs	(29)	(31)	(27)	(25)	(25)
Associates	0	0	0	0	0
Recurring non-operating income	2	0	(1)	(1)	0
Non-recurring items	(138)	(707)	0	0	0
Profit before tax	2,596	2,262	2,876	3,056	3,194
Tax	(355)	(269)	(432)	(459)	(479)
Profit after tax	2,242	1,993	2,444	2,598	2,715
Minority interests	-	-	-	-	-
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	2,242	1,993	2,444	2,598	2,715
Non-recurring items & goodwill (net)	138	707	0	0	0
Recurring net profit	2,380	2,699	2,444	2,598	2,715
Per share (THB)					
Recurring EPS *	2.73	3.10	2.80	2.98	3.11
Reported EPS	2.57	2.29	2.80	2.98	3.11
DPS	1.60	1.60	1.54	1.64	1.71
Diluted shares (used to calculate per share data)	872	872	872	872	872
Growth					
Revenue (%)	11.0	0.0	2.9	4.9	4.8
Operating EBITDA (%)	23.2	8.3	(2.6)	5.9	4.3
Operating EBIT (%)	26.2	8.6	(3.2)	6.1	4.4
Recurring EPS (%)	30.2	13.4	(9.4)	6.3	4.5
Reported EPS (%)	15.1	(11.1)	22.7	6.3	4.5
Operating performance					
Gross margin inc. depreciation (%)	44.9	45.2	45.4	45.6	45.6
Gross margin exc. depreciation (%)	46.6	47.1	47.2	47.4	47.4
Operating EBITDA margin (%)	19.3	21.0	19.8	20.0	19.9
Operating EBIT margin (%)	17.6	19.1	18.0	18.2	18.1
Net margin (%)	15.2	17.2	15.1	15.3	15.3
Effective tax rate (%)	13.7	11.9	15.0	15.0	15.0
Dividend payout on recurring profit (%)	58.6	51.7	55.0	55.0	55.0
Interest cover (X)	96.2	96.0	106.7	121.0	131.2
Inventory days	172.8	164.6	150.0	150.8	150.6
Debtor days	72.0	80.9	82.9	83.0	82.1
Creditor days	163.5	157.6	138.4	135.7	132.9
Operating ROIC (%)	56.8	58.0	47.6	47.3	47.3
ROIC (%)	37.7	39.8	33.6	34.0	34.4
ROE (%)	28.4	29.9	25.5	25.7	25.8
ROA (%) * Pre exceptional, pre-goodwill and fully diluted	17.2	19.0	17.1	17.4	17.6
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Mega We Care	8,053	8,005	8,502	9,097	9,552
Maxxcare	7,320	7,397	7,319	7,502	7,847
Sources: Mega Lifesciences: FSSIA estimates	314	280	317	327	337

Sources: Mega Lifesciences; FSSIA estimates

Financial Statements

Mega Lifesciences

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	2,380	2,699	2,444	2,598	2,715
Depreciation	272	286	297	307	316
Associates & minorities	0	0	0	0	C
Other non-cash items	474	671	(47)	(244)	(335)
Change in working capital	(989)	(1,023)	(845)	(663)	(723)
Cash flow from operations	2,136	2,633	1,850	1,998	1,973
Capex - maintenance	-	-	-	-	
Capex - new investment	(305)	(294)	(330)	(300)	(340)
let acquisitions & disposals	-	-	-	-	
Other investments (net)	24	44	0	0	(2.42)
Cash flow from investing	(281)	(250)	(330)	(300)	(340)
Dividends paid	(1,406)	(1,439)	(1,344)	(1,429)	(1,493)
quity finance	0	0	0	0	(5)
Debt finance	2	(237)	(9)	23	(5)
Other financing cash flows	(30)	(32)	(27)	(25)	(25)
cash flow from financing	(1,433)	(1,708)	(1,380)	(1,431)	(1,523
lon-recurring cash flows Other adjustments	0	0	0	0	
let other adjustments	(165)	(751)	0	0	(
Novement in cash	257	(76)	139	267	110
ree cash flow to firm (FCFF)	1,884.18	2,414.24	1,546.77	1,723.07	1,657.35
ree cash flow to equity (FCFE)	1,662.78	1,362.98	1,483.56	1,695.36	1,603.49
	1,002.10	1,002.00	1,100.00	1,000.00	1,000.10
Per share (THB)	0.40	0.77	4 77	1.00	4.00
CFF per share	2.16	2.77	1.77	1.98	1.90
CFE per share Recurring cash flow per share	1.91 3.58	1.56 4.19	1.70 3.09	1.94 3.05	1.84 3.09
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross)	4,062	4,309	4,639	4,939	5,279
ess: Accumulated depreciation	(2,161)	(2,334)	(2,631)	(2,938)	(3,254)
angible fixed assets (net)	1,901	1,974	2,008	2,001	2,025
ntangible fixed assets (net)	1,329	1,318	1,344	1,353	1,34
ong-term financial assets	0	0	0	0	
nvest. in associates & subsidiaries	223	221	221	221	22
Cash & equivalents	2,789	2,712	2,851	3,118	3,22
/C receivable	3,382	3,570	3,758	3,942	4,03
nventories	4,109	3,377	3,623	3,733	3,96
Other current assets	310	330	345	333	34
Current assets	10,590	9,990	10,578	11,126	11,56
Other assets	603	611	592	593	59
otal assets	14,646	14,115	14,743	15,294	15,75
Common equity	8,777	9,302	9,902	10,351	10,72
finorities etc.	0	0	0	0	
otal shareholders' equity	8,777	9,302	9,902	10,351	10,72
ong term debt	109	132	125	151	14
Other long-term liabilities	223	244	299	313	32
ong-term liabilities	332	376	424	464	47
VC payable	3,972	3,197	3,261	3,355	3,43
Short term debt	312	120	118	116	11
Other current liabilities	1,254	1,119	1,039	1,009	1,004
Current liabilities	5,538	4,437	4,417	4,479	4,55
otal liabilities and shareholders' equity	14,646	14,115	14,743	15,294	15,75
let working capital	2,575	2,961	3,428	3,645	3,90
nvested capital	6,632	7,086	7,592	7,813	8,08
Includes convertibles and preferred stock which is bein		,	,	,-	-,
er share (THB)					
Book value per share	10.07	10.67	11.36	11.87	12.3
angible book value per share	8.54	9.16	9.82	10.32	10.7
inancial strength	J.J 4	5.10	3.02	10.02	10.7
	(27.0)	(26.4)	(26.2)	/27 E)	(07.7
let debt/equity (%)	(27.0)	(26.4)	(26.3)	(27.5)	(27.7
let debt/total assets (%)	(16.2)	(17.4)	(17.7)	(18.6)	(18.8
Current ratio (x) CF interest cover (x)	1.9 69.5	2.3 54.0	2.4 67.6	2.5 79.4	2.
					80.
/aluation	2022	2023	2024E	2025E	20261
Recurring P/E (x) *	13.7	12.1	13.4	12.6	12.
Recurring P/E @ target price (x) *	20.5	18.1	20.0	18.8	18.
Reported P/E (x)	14.6	16.4	13.4	12.6	12.
	4.3	4.3	4.1	4.4	4.
		3.5	3.3	3.2	3.
	3.7				
rice/book (x) rice/tangible book (x)	4.4	4.1	3.8	3.6	3.
lividend yield (%) rice/book (x) rice/tangible book (x) V/EBITDA (x) **	4.4 10.0	4.1 9.2	9.4	8.8	8.
Price/book (x) Price/tangible book (x)	4.4	4.1			3. 8. 13. 3.

Sources: Mega Lifesciences; FSSIA estimates

MEGA LIFESCIENCES PCL (MEGA TB)

FSSIA ESG rating

Exhibit 4: FSSIA ESG score implication

54.48 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Source: FSSIA estimates

Exhibit 5: ESG – peer comparison

	FSSIA		Domestic ratings					Global ratings						Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
COM7	61.78		Υ	Υ	5.00	5.00	Certified	Low	47.75			52.68	21.00	4.40	43.59
MEGA	54.48		Y	Υ	4.00	4.00	Declared	Medium	66.56	-		58.59	24.00	2.39	
BJC	71.33	Υ	Y	Υ	4.00	4.00		Medium	55.09	Α		65.19	89.00	2.16	
CRC	64.49		Y	Υ	5.00	5.00	Certified	Medium		BBB		60.98	73.00	2.90	47.27

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 6: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	2.29	_
BESG environmental pillar score	_	1.86	_
BESG social pillar score	_	1.06	_
BESG governance pillar score	_	4.54	_
ESG disclosure score	44.34	53.36	_
Environmental disclosure score	29.84	44.22	_
Social disclosure score	19.44	32.16	_
Governance disclosure score	83.59	83.59	_
Environmental			
Emissions reduction initiatives	Yes	Yes	Yes
Climate change policy	Yes	Yes	No
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	_	633
GHG scope 2 location-based	_	_	6
GHG Scope 3	_	_	0
Carbon per unit of production	_	_	_
Biodiversity policy	No	No	No
Energy efficiency policy	Yes	Yes	Yes
Total energy consumption	24	24	23
Renewable energy use	1	1	1
Electricity used	12	13	12
Fuel used - natural gas	_	_	914

Sources: Bloomberg; FSSIA's compilation

Exhibit 7: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	Yes	Yes	Yes
Hazardous waste	_	_	(
Total waste	1	1	•
Waste recycled	0	0	_
Waste sent to landfills	_	_	_
Environmental supply chain management	Yes	Yes	No
Water policy	No	Yes	Yes
Water consumption	_	_	(
Social			
Human rights policy	Yes	Yes	Ye
Policy against child labor	Yes	Yes	Ye
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Ye
Gender pay gap breakout	No	No	Ne
Pct women in workforce	56	56	5
Pct disabled in workforce	_	_	_
Business ethics policy	Yes	Yes	Ye
Anti-bribery ethics policy	Yes	Yes	Ye
Health and safety policy	Yes	Yes	Ne
Lost time incident rate - employees	0	0	_
Total recordable incident rate - employees	_	_	_
Training policy	Yes	Yes	Ye
Fair remuneration policy	No	No	N
Number of employees – CSR	5,714	6,021	5,76
Employee turnover pct	_	19	_
Total hours spent by firm - employee training	70,551	79,892	70,82
Social supply chain management	Yes	Yes	Yes
Governance			
Board size	10	10	10
No. of independent directors (ID)	4	4	
No. of women on board	1	1	
No. of non-executive directors on board	8	8	
Company conducts board evaluations	Yes	Yes	Ye
No. of board meetings for the year	6	5	
Board meeting attendance pct	100	96	9
Board duration (years)	3	3	
Director share ownership guidelines	No	No	N
Age of the youngest director	32	33	3
Age of the oldest director	80	81	8
No. of executives / company managers	6	6	
No. of female executives	1	1	
Executive share ownership guidelines	No	No	N
Size of audit committee	3	3	
No. of ID on audit committee	3	3	
Audit committee meetings	4	4	
Audit meeting attendance %	100	100	10
Size of compensation committee	3	3	
No. of ID on compensation committee	1	1	
No. of compensation committee meetings	2	2	
Compensation meeting attendance %	100	100	10
Size of nomination committee	3	3	
No. of nomination committee No. of nomination committee meetings	2	2	
	100	100	10
Nomination meeting attendance %	100	100	10
Sustainability governance			

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

		•									
ESG score	Methodolog	у			Rating						
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the annu	ed on the comused and the comused in	transparent, rules-based panies' Total Sustainabil al Corporate Sustainabili anies within each industr	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I	ssessment (C ess than 45% ny are disquali	he annual S&P (SA) for DJSI. Coof the S&P Globified. The constitutions.	ompanies with oal ESG Score	an S&P Globa of the highest		
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing bu Candidates n 1) no irregula float of >150 up capital. So 70%; 2) indep wrongdoing r	siness with tr nust pass the ar trading of th shareholders ome key disquented pendent direct related to CG,	ility in Environmental and ansparency in Governan preemptive criteria, with he board members and explained to the control of t	ce, updated annually. two crucial conditions: xecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	minimum of 500 during the assess nature of the research sale and the s	% for each indessment year. Hevant industries is extended THB5b (~USI up capital for a cet capitalisation.	sion, verified dat licator, unless th The scoring will y and materiality from the THSI or 0.150b); 2) free f at least 9 out of 1 on-weighted inde mber of stocks.	e company is be fairly weigl /. ompanies who loat >20%; an l2 months. Th	a part of DJSI hted against the ose 1) market d 3) liquidity e SETTHSI		
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by th	he Thai IOD, T). The result	h in sustainable developr with support from the Sto ts are from the perspectiv s.	ck Exchange of	Good (80-89), 3 and not rated for equitable treatr	3 for Good (70 or scores belowent of shareh (25%); 4) disclo	ories: 5 for Exce 0-79), 2 for Fair (w 50. Weighting nolders (weight 2 sure & transpare	60-69), 1 for F s include: 1) th 25% combined	Pass (60-69), ne rights; 2) and l); 3) the role of		
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of su exercised. The and verifiability,	e incorporated and sufficiently e CG compon AGM proced and after the r ufficient informa second assess and 3) openne	which shareholders' rights into business operations y disclosed. All form impoents to be evaluated ann ures before the meeting meeting (10%). (The first a tion for voting; and 2) facilitates 1) the ease of attending ress for Q&A. The third involves, resolutions and voting res	s and information is ortant elements of two ually. The assessment (45%), at the meeting ssesses 1) advance ing how voting rights can be eletings; 2) transparency is the meeting minutes that	Very Good (90-		four categories (80-89), and no				
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmen policies. The (Companies de Declaration of I Certification, inc managers and	The core elements of the Checklist include corruption risk assessment, establishment of key controls, and the monitoring and developing of policies. The Certification is good for three years. (Companies deciding to become a CAC certified member start by submitting a Declaration of Intent to kick off an 18-month deadline to submit the CAC Checklist for Certification, including risk assessment, in place of policy and control, training of managers and employees, establishment of whistleblowing channels, and communication of policies to all stakeholders.)						CAC Council			
Morningstar Sustainalytics	based on an risk is unman	assessment of aged. Sources	sk rating provides an ove of how much of a compar s to be reviewed include corp	ny's exposure to ESG orate publications and			score is the sun higher ESG risk		ed risk. The		
	information, col	d availation 0 manufacture						Severe			
					0-10	10-20	20-30	30-40	40+		
ESG Book	positioned to the principle helps explain	outperform o of financial m future risk-ad ng features wi	sustainable companies the river the long term. The materiality including informational djusted performance. Ma' th higher materiality and thy basis.	ethodology considers ation that significantly teriality is applied by	scores using m	ateriality-base	ated as a weigh d weights. The s ndicating better p	score is scaled			
<u>MSCI</u>			measure a company's mand laggards according to						nethodology to		
	AAA	8.571-10.00	0					·			
	AA	7.143-8.570	Leader:	leading its industry in n	nanaging the most si	gnificant ESG ris	sks and opportuniti	es			
	Α	5.714-7.142	2								
	BBB	4.286-5.713	Average:	a mixed or unexceptior industry peers	nal track record of ma	anaging the mos	t significant ESG ri	isks and opportu	inities relative to		
	ВВ	2.857-4.285	5	, , ,							
	В	1.429-2.856	Laggard:	lagging its industry bas	ed on its high evacs	ure and failure to	n manage significa	nt ESG rieke			
	ccc	0.000-1.428	B Laggara.	agging its industry bas		unu ialluie li	anage agrilled	200 11383			
Moody's ESG			gree to which companies								
solutions			ntegrating ESG factors in or shareholders over the		d relatively outpe	rforming its pe	eers is better pos	sitioned to miti	gate risks and		
Refinitiv ESG rating	based on pub	olicly available	and objectively measure e and auditable data. The ta publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performan	nce and insufficie	ent degree of t			
S&P Global			re is a relative score mea				of ESG risks, op	portunities, ar	nd impacts		
Bloomberg	ESG Score	,	Bloomberg score evaluations score is based on Bloom	ating the company's agg	regated Environn ancial materiality.	nental, Social The score is a	a weighted gene	ralized mean	(power mean)		
		of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best. ESG Disclosure Score Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of every data point, measuring the amount of ESG data reported publicly, and not the performance on any data point.									

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Jitra Amornthum FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Jitra Amornthum started covering this stock from 20-Feb-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Mega Lifesciences	MEGA TB	THB 37.50	BUY	Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 12-Nov-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.